SUMMARY Twenty five children with chronic idiopathic thrombocytopenic purpura followed from 6-96 months in 7 Italian paediatric departments were treated with high dose immunoglobulin according to a multicentre protocol. Positive responses were observed in 20 of 25 patients (80%) and negative responses in 5 of 25 (20 %). On previous steroid treatment 7 of 10 positive responders were steroid resistant and 13 of 15 were steroid dependent. 
In 1977 Grassi and Brogi,' and more recently other authors,2-10 have shown that immunoglobulin treatment has some effectiveness in idiopathic thrombocytopenic purpura (ITP). In these studies criteria for patient selection (age, acute or chronic phase of disease) and treatment regimens differed. From these trials it emerges that the efficacy of immunoglobulin treatment depends on an intact Fc fragment that reacts with the macrophage Fc receptor.5
This multicentre study was undertaken by the Haemostasis Study Group of the Italian Association of Paediatric Haematology and Oncology and by the Italian Paediatric Immunology Study Group to determine the possible beneficial effect of immunoglobulin (Ig) in children with chronic ITP. A purified and biochemically unmodified Ig preparation Gammabulin vena (Immuno), was used.
Patients and methods
Twenty six children with chronic ITP, 17 boys and 9 girls, aged between 4 and 14 years, were studied. The results from one patient were excluded because of insufficient data, and only 25 patients were therefore evaluated. In three children the disease was aetiologically related to measles, in one child to Joint Authors: Boeri E, Rosati U, Tonini G P, Oddo 
mumps, and in five to a single episode of pharyngotonsillitis.
Criteria for patient selection were persistent thrombocytopenia from more than 6 months, with a platelet count less than 50 000/mm3 (50 x 109/l), and a normal or increased number of megakaryocytes in bone marrow aspirate. Patients were included in this study irrespective of their response (sensitivity or resistance) to previous steroid treatment and splenectomy.
Before entering the study, the children had been followed from 6-96 months (median 51 months). All had been given steroids for 1-6 months, but had stopped this treatment for at least one month before the study. Fifteen were steroid dependent, 10 steroid resistant, and two patients had undergone splenectomy.
The (1) Good response-8 patients, (Fig. 1) . (2) Intermediate response-8 patients, (Fig. 2) . (3) Poor response-4 patients, (Fig. 3) . The difference between the means of these groups is statistically significant (Student's t test) ( Children's Hospital with 2 mg/kg prednisone, the mean time to reach maximum platelet value in 30 positive responders was 10 days (unpublished data); while in the present study 16 of 20 responsive patients reached maximum response within 5 days.
Immunoglobulin treatment has the disadvantage of a frequent early relapse. In 16 of 20 (80%) patients the platelet count dropped to almost pretreatment values after four weeks. Four children, however, maintained their platelet count within the normal range after a follow up period varying from 4-12 months, and we could consider them definitively cured.
On the basis of these considerations we suggest treatment with immunoglobulin in the following cases:
(1) Where a fast increase in platelet count is required.
(2) Where steroid treatment is not indicated or is ineffective.
(3) As a substitute for immunosuppressive treatment, the use of which should be limited by its adverse effects.
(4) As an attempt to avoid splenectomy. Our results allowed us to divide patients into groups according to their clinical response. On the basis of the treatment response there were positive or negative responders. Positive responders were themselves divided into three groups according to the degree of increase in the platelet count and to the time taken to obtain a notable response (Table 1) . These groups were: good response, intermediate response, and poor response.
After the fourth immunoglobulin injection the difference between the groups was already considerable, but it became more evident after the fifth injection ( Table 2) .
The possibility of predicting the type of response would be extremely interesting clinically. We carefully examined our 25 patients looking for a correlation between response and: age, sex, anamnesis (with particular attention to exanthematous diseases), duration of thrombocytopenia, results of previous steroid treatment, and platelet count before immunoglobulin treatment. Unfortunately, however, no parameter assumed a predictive value. 
